XML 39 R29.htm IDEA: XBRL DOCUMENT v3.25.1
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 20, 2025
Feb. 14, 2025
Feb. 06, 2024
Feb. 05, 2024
Feb. 28, 2025
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Cash issuance costs           $ 33,608  
Shares held in abeyance           1,138,055 1,351,580  
Options granted           2,152,908    
Exercise price of options granted           $ 2.46    
Weighted average grant date fair value of stock options granted           $ 1.88 $ 1.11  
Issuance and sale of common stock, net of issuance costs [1]           $ 901,610    
Net proceeds from shares sold           1,083,915  
Deferred offering costs reclassified to additional paid-in capital           $ 148,697    
Shares issued upon exercise of options           29,249    
Exercise price of options exercised           $ 1.45    
Gross proceeds from exercise of options           $ 42,411  
Share-Based Payment Arrangement, Option [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Options granted   2,152,908            
Exercise price of options granted   $ 2.46            
Grant date fair value of options granted   $ 4,044,250            
Vesting of options description   (i) options to purchase an aggregate 323,459 shares of common stock vest monthly over one year, and (ii) options to purchase an aggregate of 1,829,449 shares of common stock vest to the extent of 50% immediately with the remainder vesting quarterly over two years commencing one year from the date of grant            
Common Stock [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Warrants exercisable     3,351,580          
Exercise price     $ 2.33          
Proceeds from exercise of warrants     $ 8,100,000          
Cash issuance costs     $ 595,364          
Number of shares sold [1]           492,087    
Shares issued           2,213,525    
Issuance and sale of common stock, net of issuance costs [1]           $ 49    
Abeyance shares issued           63,525    
Shares issued upon exercise of options           29,249    
Common Stock [Member] | Roth Capital Partners LLC [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Cash fee for services       $ 528,000        
Common Stock [Member] | Private Placement [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Warrants exercisable     2,513,686          
Exercise price     $ 2.43          
Warrants for cash and the payment     $ 0.125          
Common Stock [Member] | 2024 ATM Program [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Number of shares sold         492,087 492,087    
Weighted-average gross price per share         $ 2.20      
Issuance and sale of common stock, net of issuance costs         $ 1,083,915 $ 1,100,000    
Commissions, legal and accounting fees           33,608    
Net proceeds from shares sold           $ 1,050,307    
Common Stock [Member] | Auctus Fund, LLC [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Number of shares sold 63,525             1,201,580
Abeyance shares issued           63,525    
Warrant [Member] | Roth Capital Partners LLC [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Issuance costs             $ 595,364  
[1] Represents the gross proceeds of $1,083,915, less issuance costs of $182,305, resulting in net proceeds of $901,610. See Note 4 - Stockholders’ Equity - ATM Sales for additional details.